Cases That Test Your Skills

Opioid use remits, depression remains

Current Psychiatry. 2014 August;13(8):45-50

References

1. Tan EM, Eiger RI, Roth JD. A life of drugs and ‘downtime.’ Current Psychiatry. 2007;6(8):98-103.
2. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC, American Psychiatric Association; 2000.
3. McLellan AT, Lewis DC, O’Brien CP, et al. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284(13):1689-1695.
4. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression? J Mol Neurosci. 2002; 18(1-2):143-149.
5. Sikka P, Kaushik S, Kumar G, et al. Study of antinociceptive activity of SSRI (fluoxetine and escitalopram) and atypical antidepressants (venlafaxine and mirtazepine) and their interaction with morphine and naloxone in mice. J Pharm Bioallied Sci. 2011;3(3):412-416.
6. Kabat-Zinn J. Full catastrophe living. 15th ed. New York, NY: Bantam Books; 1990.
7. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach for preventing relapse. New York, NY: Guilford Press; 2002.
8. Koob GF. The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res. 2010;1314:3-14.
9. Laurent H, Laurent S, Hertz R, et al. Sex-specific effects of mindfulness on romantic partners’ cortisol responses to conflict and relations with psychological adjustment. Psychoneuroendocrinology. 2013;38(12):2905-2913.
10. Siegel DJ. The mindful brain: reflection and attunement in the cultivation of well-being. New York, NY: W.W. Norton & Company; 2007.
11. Davidson RJ, McEwen BS. Social influences on neuroplasticity: stress and interventions to promote well-being. Nat Neurosci. 2012;15(5):689-695.
12. Bowen S, Chawla N, Collins SE, et al. Mindfulness-based prevention for substance use disorders: a pilot efficacy trial. Subst Abus. 2009;30(4):295-305.
13. Grossman P. Defining mindfulness by how poorly I think I pay attention during everyday awareness and other intractable problems for psychology’s (re)invention of mindfulness: comment on Brown et al. (2001). Psychol Assess. 2011;23(4):1034-1040; discussion 1041-1046.
14. Koola MM, Fawcett JA, Kelly DL. Case report on the management of depression in schizoaffective disorder, bipolar type focusing on lithium levels and measurement-based care. J Nerv Ment Dis. 2011;199(12):989-990.
15. Nock MK, Hwang I, Sampson N, et al. Cross-national analysis of the associations among mental disorders and suicidal behavior: findings from the WHO World Mental Health Surveys. PLoS Med. 2009;6(8):e1000123. doi: 10.1371/journal.pmed.1000123.

Stable. He became more emotionally stable. He did not have the urge to use drugs and he did not relapse.

As we hypothesized, for Mr. B, practicing MBI was associated with abstinence from substance use, increased mindfulness, acceptance of mental health problems, and remission of psychiatric symptoms.

Bottom Line
Mindfulness-based interventions provide patients with tools to target symptoms such as poor affect regulation, poor impulse control, and rumination. Evidence supports that using MBI in addition to the usual treatment can prevent relapse of a substance use disorder.

Related Resources
• Sipe WE, Eisendrath SJ. Mindfulness-based cognitive therapy: theory and practice. Can J Psychiatry. 2012;57(2):63-69.• Lau MA, Grabovac AD. Mindfulness-based interventions: Effective for depression and anxiety. Current Psychiatry. 2009;8(12):39-55.

Drug Brand Names
Aripiprazole • Abilify Mirtazapine • Remeron
Buprenorphine/naloxone • Quetiapine • Seroquel
Suboxone
Bupropion • Wellbutrin Sertraline • Zoloft
Duloxetine • Cymbalta Trazodone • Desyrel
Methadone • Dolophine Venlafaxine • Effexor
Methylphenidate • Ritalin, Concerta

Acknowledgement
The manuscript preparation of Maju Mathew Koola, MD, DPM was supported by the NIMH T32 grant MH067533-07 (PI: William T. Carpenter, MD) and the American Psychiatric Association/Kempf Fund Award for Research Development in Psychobiological Psychiatry (PI: Koola). The treating Psychiatrist PGY-5 (2011-2012) Addiction Psychiatry fellow (Dr. Varghese) was supervised by Dr. Eiger. Drs. Koola and Varghese contributed equally with the manuscript preparation and are joint first authors. Dr. Varghese received a second prize for a poster presentation of this case report at the 34th Indo American Psychiatric Association meeting in San Francisco, CA, May 19, 2013. Christina Mathew, MD, also contributed with manuscript preparation.

Disclosures
The authors report no financial relationship with any company whose products are mentioned in this article or with manufactures of competing products.

Opioid use remits, depression remains

References

Pages

Recommended Reading

Related Articles

Cases That Test Your Skills

A life of drugs and ‘downtime’